Abstract
Peroxisome proliferator-activated receptor (PPAR) is involved in the pathology of numerous diseases including obesity, diabetes, and atherosclerosis, because of its role in decreasing insulin resistance and inflammation. Type 2 diabetes mellitus and obesity are the most frequent endocrine-metabolic diseases and their pathogenic basis are characterized by insulin resistance and insulin secretion defects that can be demonstrated through several alterations in carbohydrates, lipids, and protein metabolism. For that reason a class of compounds, called thiazolidinediones, has been developed for the management of type 2 diabetes mellitus. Thiazolidinediones are PPAR-γ agonists regulating the expression of several genes involved in the regulation of glucose, lipid and protein metabolism, enhancing the action of insulin in insulin-sensitive tissue by increasing glucose uptake in skeletal muscle and adipose tissue, and decreasing hepatic glucose production. Pioglitazone is the only available PPAR-γ agonist for the treatment of type 2 diabetes after rosiglitazone withdrawal from several countries. This review discusses the safety and effectiveness of pioglitazone in the clinical practice for the treatment of type 2 diabetes mellitus.
Keywords: Inflammation, insulin resistance, pioglitazone, PPAR-γ, thiazolidinediones
Current Molecular Pharmacology
Title:Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Volume: 5
Author(s): Giuseppe Derosa and Pamela Maffioli
Affiliation:
Keywords: Inflammation, insulin resistance, pioglitazone, PPAR-γ, thiazolidinediones
Abstract: Peroxisome proliferator-activated receptor (PPAR) is involved in the pathology of numerous diseases including obesity, diabetes, and atherosclerosis, because of its role in decreasing insulin resistance and inflammation. Type 2 diabetes mellitus and obesity are the most frequent endocrine-metabolic diseases and their pathogenic basis are characterized by insulin resistance and insulin secretion defects that can be demonstrated through several alterations in carbohydrates, lipids, and protein metabolism. For that reason a class of compounds, called thiazolidinediones, has been developed for the management of type 2 diabetes mellitus. Thiazolidinediones are PPAR-γ agonists regulating the expression of several genes involved in the regulation of glucose, lipid and protein metabolism, enhancing the action of insulin in insulin-sensitive tissue by increasing glucose uptake in skeletal muscle and adipose tissue, and decreasing hepatic glucose production. Pioglitazone is the only available PPAR-γ agonist for the treatment of type 2 diabetes after rosiglitazone withdrawal from several countries. This review discusses the safety and effectiveness of pioglitazone in the clinical practice for the treatment of type 2 diabetes mellitus.
Export Options
About this article
Cite this article as:
Derosa Giuseppe and Maffioli Pamela, Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk, Current Molecular Pharmacology 2012; 5 (2) . https://dx.doi.org/10.2174/1874467211205020272
DOI https://dx.doi.org/10.2174/1874467211205020272 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
Call for Papers in Thematic Issues
Common mechanisms underpinning neurodevelopmental disorders and psychiatric diseases
A growing number of large-scale epidemiologic studies has strongly suggested that common mechanisms may be shared by aberrant brain development and psychiatric disorders. There is now an appreciation of synergic roles of genetic variants and environmental stress which profoundly affect the genome integrity and reshape brain development. This can lead ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Multiple Roles of The Transcription Factors MAZ and Pur-1, Two Proteins encoded by Housekeeping Genes
Current Genomics Coronavirus-related Disease Pandemic: A Review on Machine Learning Approaches and Treatment Trials on Diagnosed Population for Future Clinical Decision Support
Current Medical Imaging Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry Advancements in the Anti-Diabetes Chemotherapeutics Based on Amino Acids, Peptides, and Peptidomimetics
Mini-Reviews in Medicinal Chemistry Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry The Story of SPATA2 (Spermatogenesis-Associated Protein 2): From Sertoli Cells to Pancreatic Beta-Cells
Current Genomics Is Whole-Body Thermoregulatory Function Impaired in Type 1 Diabetes Mellitus?
Current Diabetes Reviews Dietary Factors Influencing Magnesium Absorption in Humans
Current Nutrition & Food Science Fad Diets: Dietary Dilemmas, Predicaments, and Recommendations for its Use
Current Nutrition & Food Science Relationship Between Na<sup>+</sup>, K<sup>+</sup>-ATPase and NMDA Receptor at Central Synapses
Current Protein & Peptide Science Emerging Therapy for Diabetic Neuropathy: Cell Therapy Targeting Vessels and Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Leukocytes in Diabetic Retinopathy
Current Diabetes Reviews Other Activities
Current Bioactive Compounds Role of Phytomolecules in the Treatment of Obesity: Targets, Mechanisms and Limitations
Current Topics in Medicinal Chemistry Structural Basis for the Design of PPAR-γ Ligands: A Survey on Quantitative Structure- Activity Relationships
Mini-Reviews in Medicinal Chemistry Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
Current Hypertension Reviews Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules
Current Topics in Medicinal Chemistry Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin
Current Vascular Pharmacology Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry